Franco Felizarta

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Pedro Cahn, Anton Pozniak, Horacio Mingrone et al. · The Lancet · 2013 · 507 citations · Full text

Treatment And Prevention, Week 48, Antiviral Drug Development +7

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

Stefan Zeuzem, Graham R. Foster, Stanley Wang et al. · New England Journal of Medicine · 2018 · 426 citations · Full text

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

Xavier Forns, Samuel S. Lee, Joaquin Valdes et al. · The Lancet Infectious Diseases · 2017 · 338 citations

Hepatology, Hepatitis C, Viral Hepatitis +11

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis

Paul Y. Kwo, Fred Poordad, Armen Asatryan et al. · Journal of Hepatology · 2017 · 296 citations · Full text

Diagnostic Virology, Hepatology, Hepatitis C +9

Brief Report

Sharon Walmsley, Axel Baumgarten, Juan Berenguer et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2015 · 215 citations · Full text

Noninferiority Study, Immunodeficiencies, Single Study +12